Indoco Remedies Limited announced the outcome of its Board Meeting held on May 7, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditors' reports which expressed an unmodified opinion. Additionally, the Board recommended a dividend of ₹0.20 per equity share on a face value of ₹2/- for the financial year 2025-2026, subject to approval from the shareholders at the upcoming 79th Annual General Meeting. The Board meeting commenced at 11:05 a.m. and concluded at 12:30 p.m. The company also provided press releases and detailed financial statements, including standalone and consolidated income statements, balance sheets, and cash flow statements.
